Maynard Cooper’s lawyers provide clients in the life sciences industry with a comprehensive range of legal services throughout the full life cycles of their products. From initial entity formation and intellectual property protection to drug and medical device approvals, patent litigation and product liability litigation, pharmaceutical, biotechnology and medical device companies routinely call on Maynard Cooper to help them navigate the changing landscapes of these rapidly evolving fields.
We are client-driven and have decades of experience working for major life sciences research institutions and representing and advising companies large and small in all aspects of their businesses. We know the science and the technology — our team includes lawyers with advanced degrees who stand by our clients at the intersection between complex scientific and clinical issues and the law.
Maynard Cooper lawyers have experience advising life sciences clients involved in a wide range of areas, including biologics, biosimilars, pharmaceuticals, medical devices, diagnostic technologies and drug delivery systems. Exemplary small and large molecules that Maynard Cooper’s Life Sciences Group have worked on include high profile pharmaceuticals and biologics such as Oxycodon/Oxycontin, Sildenafil/Viagra, Neupogen/Filgrastim, Tramadol/Ultram, Epinephrine/EpiPen, Mirapex/Pramipexole, Nitrofurantorin/Macrobid,Timoptic/Timolol Maleate, Hepatitis C Protease Tobi/Tobramycin, and Interferon.
Our multidisciplinary life sciences team includes lawyers with expertise in key areas of law that impact life sciences companies, including corporate formation, intellectual property, regulatory matters including approvals, healthcare, litigation, products liability and class actions.
Intellectual property is at the heart of the life sciences industry. We offer clients a full range of intellectual property legal services and advice for their products, from transactional to litigation matters. Our intellectual property lawyers have extensive experience in patent and trademark prosecution, licensing and portfolio management. Our team also has extensive experience in patent litigation, including Hatch-Waxman litigation, and appeals to the Court of Appeals to the Federal Circuit.
Maynard Cooper’s roots in the life sciences go back several decades to the establishment of Alabama’s two major biotech centers: Birmingham and Huntsville. The medical and engineering schools at the University of Alabama at Birmingham (“UAB”) attract world class engineers, physicians and researchers, who have been at the leading edge of innovation in biotechnology and life sciences for more than 50 years. Examples of these kinds of innovators include Southern Research Institute (“SRI”) and Innovation Depot. SRI is a self-sustaining, not-for-profit research organization that has made advancements in drug discovery and pre-clinical drug development for decades. Maynard Cooper lawyers have served on SRI’s board of directors and regularly represent SRI in corporate and litigation matters.
Innovation Depot is a business incubation facility that works in conjunction with UAB. Innovation Depot focuses primarily on developing biotechnology, life science, engineering and other service businesses. The National Business Incubation Association recently awarded Innovation Depot the 2011 Dinah Adkins Incubator of the Year award in the technology focus category. Maynard Cooper represents Innovation Depot and many of its client companies.
Huntsville is home to NASA’s Marshall Space Flight Center, which has played a central role in the country’s space program. Huntsville is also home to Cummings Research Park, one of the world’s leading science and technology business parks. Many of the companies that Maynard Cooper represents operate facilities in Cummings are involved in some facet of aerospace or engineering. Cummings also boasts one of the newest and best funded biotechnology institutes in the country – HudsonAlpha Institute for Biotechnology.
HudsonAlpha is a not-for-profit organization that has received both public and private funding. Its 270,000 square-foot facility in Cummings Research Park houses several research labs and associated companies. Much of HudsonAlpha’s research focuses on genomics and is designed to improve human health, spark economic development and educate the public. Maynard Cooper has and continues to work with HudsonAlpha and several of its associated companies to help support HudsonAlpha’s mission. Clearview Cancer Institute, an affiliate of Oncology Specialties, P.C., and a client of Maynard Cooper, collaborates with HudsonAlpha on ongoing cancer research.
- Abbott Laboratories, Inc.
- Amgen, Inc.
- Baxter Healthcare Corporation
- Cardinal Health, Inc.
- Glaxo, Inc.
- Hoffmann La-Roche, Inc.
- Southern Research Institute
- Surmodics/Brookwood Pharmaceuticals, Inc.
- Merck KGaA
Birmingham, Al. Maynard Cooper & Gale is pleased to announce that Raymond L. Bell, Jr. has joined the Firm as a Shareholder in the Government Solutions Practice Group of the Corporate Section. Bell will practice out of both the Mobile…
On November 20, 2018, Leland Murphree will be on a webinar panelist for the American Bankruptcy Institute, “Hot Issues in the Ongoing Third Party Release Debates.”